Cystic Fibrosis Therapeutics Market

Cystic Fibrosis Therapeutics Market by Drug Classes (Bronchodilators, CFTR Modulators, Pancreatic Enzyme Supplements, and Mucolytics), Routes of Administration (Inhaled Drugs and Oral Drugs), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

  • Report ID: HC-2261
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 166
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global cystic fibrosis therapeutics market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to rise in the incidence of cystic fibrosis. One of the other key factors expected to boost the growth of the market is an increase in the rate of treatment for cystic fibrosis. Moreover, the favorable government regulations to support the development of advanced drugs for the treatment are anticipated to help the market growth.

Cystic Fibrosis Therapeutics Market Key Takeaways

Cystic fibrosis is a rare and serious life-threatening disease that is genetic in nature caused by the alteration of cystic fibrosis transmembrane conductance regulator (CFTR). The genetic disorder can cause damage to the digestive system and lungs as well as affect cells that produce digestive juices sweat and mucus gets sticky and thick. The data published by the Cystic Fibrosis Foundation states that such genetic disorders are increasing continuously. The number of patients increased from 26,366 in 2010 to 28,983 in 2015. Due to the increase in the number of patients, there is increasing demand for cystic fibrosis that is effective and efficient. Pancreatic enzyme supplements, bronchodilators drugs, anti-inflammatory drugs, mucolytic drugs, anti-infective, antibiotics (oral, inhaled, or parental feeding formulae), and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are some of the approved drugs that are commercially available.

In order to broaden the base target patient with the present drug portfolio, several clinical trials are being conducted at a regular basis. AZD-5634; PTI-428; QR-010; POL-6014; and VX-445 + tezacaftor + ivacaftor are some of the main pipelined drugs for the treatment of the disorder. Various activities associated with Cystic fibrosis are performed by non-profit organizations including Cystic Fibrosis Worldwide, Cystic Fibrosis Foundation, South African Cystic Fibrosis Association, South African Cystic Fibrosis Trust, and Cystic Fibrosis Canada.

Market Trends, Drivers, Restraints, and Opportunities

  • Rise in funding for research and development by both public and private organizations is anticipated to boost the growth of the market.
  • Increase in the number of healthcare initiatives taken by both the government and non-profit organizations in order to raise awareness of the disorder among people is one of the key driving factors of the market.
  • Availability of favorable reimbursement policies and rapid development of new drugs for the treatment are another major factors helping the market growth.
  • Potential candidates for the clinical pipeline are increasing and rising approval of the drugs are some key driving factors of the market.
  • High cost of the treatment of this disease is proved to be a restraining factor and is expected to hinder the growth of the market.

Scope of the Report

The report on the global cystic fibrosis therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also
been included in the report.

Attributes

Details

Report Title

Cystic Fibrosis Therapeutics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drug Classes (Bronchodilators, CFTR Modulators, Pancreatic Enzyme Supplements, and Mucolytics) and Routes of Administration (Inhaled Drugs and Oral Drugs)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

AstraZeneca; AbbVie, IncGilead; Novartis AG; Alaxia; Vertex Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; AIT (Advanced Inhalation Therapies); Alcresta Therapeutics, Inc.; Allergan; and F. Hoffmann-La Roche Ltd.

Market Segment Insights

Modulators segment is anticipated to expand at a high growth rate

Based on drug classes, the global cystic fibrosis therapeutics market is categorized as bronchodilators, CFTR modulators, pancreatic enzyme supplements, and mucolytics. In the treatment of cystic fibrosis, the chief contemplation is the management of nutritional therapy, controlling respiratory infection while maintaining the functioning of the lungs, and controlling complications. The first CFTR modulator drug was launched in 2014 named Kalydeco and was the only drug till 2014. The CFTR modulators segment dominated the market with the major revenue share of the market in 2019 and is anticipated to expand at a high growth rate during the projected period owing to the launch of new drugs including Orkambi. This drug enables the correcting of the defective function of the protein.

Cystic Fibrosis Therapeutics Market By Drug Classes

Oral drugs segment is expected to grow at a significant pace

Based on the routes of administration, the market is bifurcated into inhaled drugs and oral drugs. The oral drugs segment held a major share of the market in 2019 and is expected to grow at a significant pace in the targeted years attributed to ease of use without the help of any professional. The growth of the market is also dependant on the increasing awareness regarding the benefits of oral drugs. Pancreatic enzyme supplements including Viokace, Creon/Zenpep, Ultresa, and PERTZYE and CFTR modulators including ORKAMBI and KALYDECO are some of the therapeutics that are approved. These drugs are high in demand and are commercially available on a huge basis, which is expected to boost the growth of the market segment. A rise in the number of clinical trials is another key factor that helps the segment growth along with an increase in investments made by the public and private organizations.

Asia Pacific market is anticipated to register a healthy CAGR

In terms of regions, the global cystic fibrosis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to hold a large share of the market in the coming years due to a high number of people being affected with cystic fibrosis and several initiatives taken by Cystic Fibrosis Canada and Cystic Fibrosis Foundation. On the other hand, the Asia Pacific market is anticipated to register a healthy CAGR during the forecast period attributed to increase in awareness regarding cystic fibrosis and wide availability of the treatment options. Moreover, the development of the economy and an increase in the development of healthcare facilities present another key drivers of the regional market growth.

Cystic Fibrosis Therapeutics Market By Regions

Segments


Segments Covered in the Report
The global cystic fibrosis therapeutics market has been segmented on the basis of

Drug Classes
  • Bronchodilators
  • CFTR Modulators
  • Pancreatic Enzyme Supplements
  • Mucolytics
Routes of Administration
  • Inhaled Drugs
  • Oral Drugs
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • AstraZeneca
  • AbbVie
  • IncGilead
  • Novartis AG
  • Alaxia
  • Vertex Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • AIT (Advanced Inhalation Therapies)
  • Alcresta Therapeutics, Inc.
  • Allergan
  • F. Hoffmann-La Roche Ltd.

Competitive Landscape

Key players competing in the global cystic fibrosis therapeutics market are AstraZeneca; AbbVie, IncGilead; Novartis AG; Alaxia; Vertex Pharmaceuticals Inc,; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; AIT (Advanced Inhalation Therapies); Alcresta Therapeutics, Inc.; Allergan; and F. Hoffmann-La Roche Ltd. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.

Cystic Fibrosis Therapeutics Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cystic Fibrosis Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cystic Fibrosis Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cystic Fibrosis Therapeutics Market - Supply Chain
  4.5. Global Cystic Fibrosis Therapeutics Market Forecast
     4.5.1. Cystic Fibrosis Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cystic Fibrosis Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cystic Fibrosis Therapeutics Market Absolute $ Opportunity
5. Global Cystic Fibrosis Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Cystic Fibrosis Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Cystic Fibrosis Therapeutics Demand Share Forecast, 2019-2026
6. North America Cystic Fibrosis Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Cystic Fibrosis Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Cystic Fibrosis Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Cystic Fibrosis Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Cystic Fibrosis Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Cystic Fibrosis Therapeutics Demand Share Forecast, 2019-2026
8. Europe Cystic Fibrosis Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Cystic Fibrosis Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Cystic Fibrosis Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Cystic Fibrosis Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Cystic Fibrosis Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Cystic Fibrosis Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Cystic Fibrosis Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Cystic Fibrosis Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Cystic Fibrosis Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Cystic Fibrosis Therapeutics Market: Market Share Analysis
  11.2. Cystic Fibrosis Therapeutics Distributors and Customers
  11.3. Cystic Fibrosis Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. AstraZeneca AbbVie IncGilead Novartis AG Alaxia Vertex Pharmaceuticals Inc.  

Segments Covered in the Report
The global cystic fibrosis therapeutics market has been segmented on the basis of

Drug Classes
  • Bronchodilators
  • CFTR Modulators
  • Pancreatic Enzyme Supplements
  • Mucolytics
Routes of Administration
  • Inhaled Drugs
  • Oral Drugs
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • AstraZeneca
  • AbbVie
  • IncGilead
  • Novartis AG
  • Alaxia
  • Vertex Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • AIT (Advanced Inhalation Therapies)
  • Alcresta Therapeutics, Inc.
  • Allergan
  • F. Hoffmann-La Roche Ltd.

Key players competing in the global cystic fibrosis therapeutics market are AstraZeneca; AbbVie, IncGilead; Novartis AG; Alaxia; Vertex Pharmaceuticals Inc,; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; AIT (Advanced Inhalation Therapies); Alcresta Therapeutics, Inc.; Allergan; and F. Hoffmann-La Roche Ltd. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.

Cystic Fibrosis Therapeutics Market By Key Players

Buy Report